O Glidewell
About
In The Last Decade
O Glidewell
10 papers receiving 172 citations
Peers
Comparison fields: 5 of 40
- Pathology and Forensic Medicine 68
- Oncology 59
- Pulmonary and Respiratory Medicine 52
- Hematology 41
- Public Health, Environmental and Occupational Health 40
Countries citing papers authored by O Glidewell
This map shows the geographic impact of O Glidewell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O Glidewell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O Glidewell more than expected).
Fields of papers citing papers by O Glidewell
This network shows the impact of papers produced by O Glidewell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O Glidewell. The network helps show where O Glidewell may publish in the future.
Co-authorship network of co-authors of O Glidewell
This figure shows the co-authorship network connecting the top 25 collaborators of O Glidewell. A scholar is included among the top collaborators of O Glidewell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O Glidewell. O Glidewell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 37 | |
| 2 | Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. | 43 |
| 3 | Osteogenic sarcoma studies by the Cancer and Leukemia Group B. | 5 |
| 4 | Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast. | 33 |
| 5 | Chemoimmunotherapy in acute myelocytic leukemia. | 11 |
| 6 | Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). | 11 |
| 7 | Cytomorphological determinants of prognosis in acute lymphoblastic leukemia of children. | 22 |
| 8 | Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-67574) plus prednisone in advanced childhood acute lymphocytic leukemia. | 6 |
| 9 | Treatment of adult leukemia with L-asparaginase (NSC-109229). | 25 |
| 10 | Failure of hydroxyurea (NSC-32065) and prednisone (NSC-10023) in the treatment of acute myelocytic leukemia. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.